Cite
HARVARD Citation
Bardia, A. et al. (2017). Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort. Breast. pp. S46-S47. [Online].